Efficacy of femtosecond laser-assisted cataract surgery for atopic cataract

Session Details

Session Title: Femtolaser-Assisted Cataract Surgery (FLACS) II

Session Date/Time: Monday 09/10/2017 | 08:30-10:30

Paper Time: 08:54

Venue: Room 4.4

First Author: : K.Yamazaki JAPAN

Co Author(s): :    R. Kimoto   Y. Shibata   J. Yoneyama   M. Inagaki   T. Hayashi   T. Mimura     

Abstract Details

Purpose:

To evaluate the efficacy and safety of femtosecond laser-assisted cataract surgery (FLACS) for atopic cataract

Setting:

Omiya Nanasato Eye Institute, Saitama, Japan

Methods:

Atopic cataract cases (37 eyes of 30 cases, male 34 eyes, female 3 eyes) undergoing FLACS using LenSx (Alcon) between June 2012 and December 2016 were included in this retrospective study. Patients underwent corneal incisions, anterior capsulotomies and lens fragmentation. One eye had an iris cyst, one eye had LASIK, and one eye had scleral buckling. Two eyes (2 cases) had keratoconus, one of which had corneal opacity, and a monofocal intraocular lens (IOL) was implanted in this case. In the remainder of cases multifocal IOLs were implanted. All surgeries were performed by a single surgeon.

Results:

A free-floating capsulotomy was achieved in 32 eyes (86%). Anterior subcapsular fibrosis was observed in 13 eyes, including 3 eyes with fibrosis extending across the line of capsulotomy requiring manual excision. Nine eyes had intumescent white cataract (IWC). Incomplete capsulotomies due to anterior capsular tags were present in 4 eyes in the IWC group, which was significantly higher compared to other cases (p<0.05). The scleral buckling case had weak zonules. Radial anterior capsular tear, vitreous loss, and IOL dislocation did not occur. Best corrected distance visual acuity was 0.95 (pre-op, logMAR) and 0.03 (post-op).

Conclusions:

FLACS can be performed safely in atopic cataract, despite the presence of anterior subcapsular fibrosis and/or intumescent white cataract. Proper centration of IOL was achieved in all cases without major complications.

Financial Disclosure:

NONE